PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22425996-7 2012 We observed that the addition of selumetinib provided substantial benefit for mice with lung cancer caused by Kras and Kras and p53 mutations, but mice with Kras and Lkb1 mutations had primary resistance to this combination therapy. AZD 6244 33-44 Kirsten rat sarcoma viral oncogene homolog Mus musculus 110-114 30021885-7 2018 Treatment with an orally bioavailable small-molecule activator of PP2A DT-061, in combination with the MEK inhibitor AZD6244, resulted in suppression of both p-AKT and MYC, as well as tumor regression in two KRAS-driven lung cancer mouse models. AZD 6244 117-124 Kirsten rat sarcoma viral oncogene homolog Mus musculus 208-212 29348467-5 2018 Treatment with U0126, PD901, and Selumetinib MEK inhibitors triggered growth restraint in all CCA cell lines tested, with the most pronounced growth suppressive effects being observed in K-Ras mutant cells. AZD 6244 33-44 Kirsten rat sarcoma viral oncogene homolog Mus musculus 187-192 25541062-0 2015 AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. AZD 6244 0-7 Kirsten rat sarcoma viral oncogene homolog Mus musculus 106-111 25541062-6 2015 The combination of cisplatin and AZD6244 yielded a superior response to cisplatin alone in K-ras mice. AZD 6244 33-40 Kirsten rat sarcoma viral oncogene homolog Mus musculus 91-96 31804471-4 2019 We also examined functional roles for Kras activation in dysplasia progression using Selumetinib, a MEK inhibitor, which is a downstream mediator of Kras signaling. AZD 6244 85-96 Kirsten rat sarcoma viral oncogene homolog Mus musculus 149-153 29945997-7 2018 Interestingly, p53 co-mutation rendered KRASG12C lung tumors less sensitive to combination treatment with selumetinib and chemotherapy.Conclusions: Our data demonstrate that unique KRAS mutations and concurrent mutations in tumor-suppressor genes are important factors for lung tumor responses to MEK inhibitor. AZD 6244 106-117 Kirsten rat sarcoma viral oncogene homolog Mus musculus 40-44 28938614-0 2017 Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. AZD 6244 46-57 Kirsten rat sarcoma viral oncogene homolog Mus musculus 61-65 28938614-11 2017 Irrespective of LKB1 status, phenformin may enhance the anti-tumor effect of selumetinib in KRAS-mutant NSCLC. AZD 6244 77-88 Kirsten rat sarcoma viral oncogene homolog Mus musculus 92-96 22425996-7 2012 We observed that the addition of selumetinib provided substantial benefit for mice with lung cancer caused by Kras and Kras and p53 mutations, but mice with Kras and Lkb1 mutations had primary resistance to this combination therapy. AZD 6244 33-44 Kirsten rat sarcoma viral oncogene homolog Mus musculus 119-123 22425996-7 2012 We observed that the addition of selumetinib provided substantial benefit for mice with lung cancer caused by Kras and Kras and p53 mutations, but mice with Kras and Lkb1 mutations had primary resistance to this combination therapy. AZD 6244 33-44 Kirsten rat sarcoma viral oncogene homolog Mus musculus 119-123 34856074-6 2022 We demonstrate that SRC is activated in response to treatment of KRAS-mutant colorectal cell lines with MEK inhibitors (trametinib or AZD6244), and that AZD0424 abrogates this. AZD 6244 134-141 Kirsten rat sarcoma viral oncogene homolog Mus musculus 65-69